Hikal Ltd.

₹202.1

0.3 (0.1%)

HIKAL Share Price

Pharmaceuticals & Biotechnology

As on October 28, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 2,495.61 Cr

P/E Ratio-51.15

Dividend Yield0.15 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	199.14	Bullish
10-DMA	207.45	Bearish
20-DMA	212.33	Bearish
50-DMA	216.5	Bearish
100-DMA	216.09	Bearish
200-DMA	204.21	Bearish

Historical Performance

1 Year

-15.8%

3 Years

-25.7%

5 Years

-64.6%

10 Years

39.1%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	17,126	18,598	17,846	20,230	19,427
Total Expenditure	14,922	15,314	15,176	17,660	16,022
Other Income	123	50	25	54	49
Operating Profit	2,327	3,334	2,695	2,625	3,454
Interest	621	752	564	481	312
Depreciation	1,638	1,344	1,176	1,090	957
Profit Before Tax	-783	1,238	955	1,054	2,186
Consolidated Net Profit	-488	908	696	784	1,605
Adjusted EPS	-4	7	6	6	13

Compounded Sales Growth

10 Years:13.1

5 Years:-0.1

3 Years:-3.3

TTM:-1.6

Compounded Profit Growth

10 Years:-16.3

5 Years:-33.8

3 Years:-26.4

TTM:-28.5

Stock Price CAGR

10 Years:3.4

5 Years:-18.9

3 Years:-9.4

TTM:-16.3

Return on Equity

10 Years:5.5

5 Years:13

3 Years:5.6

last year:-4

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	247	247	247	247	247
Total Reserves	11,741	12,376	11,630	11,088	10,433
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	4,877	5,331	6,430	5,905	4,319
Other Current Liabilities	1,933	1,921	1,728	1,575	2,321
Short Term Borrowings	1,785	2,633	2,886	1,733	2,726
Total Liabilities	23,654	28,062	27,635	23,855	23,280
Capital Work in Progress	945	1,212	4,143	4,021	2,852
Long Term Loans & Advances	435	925	1,294	759	1,288
Currents Investments	---	---	---	---	103
Short Term Loans and Advances	590	3,249	2,480	1,030	1,741
Total Current Assets	8,841	12,167	11,428	9,390	10,232
Total Assets	23,654	28,062	27,635	23,855	23,280
Adjusted Book Value	97	102	96	92	87

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a low PE of -51.15, which may indicate undervaluation or subdued growth expectations.
Over the last three years, the stock delivered a weak 3-year price CAGR of -9.7%, indicating poor shareholder returns.
The stock carries a high beta of 1.6, implying higher volatility and elevated risk.
In the last financial year, the company reported an EBITDA of ₹2327 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹17126 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 836679.8

No. of Shares: 4140 (Approx)

Performance:-16.3%

-163320.2

NIFTY Performance: -12.9%

1 day Top Gainers